GeneDx (WGS) versus Its Competitors Head-To-Head Comparison

GeneDx (NASDAQ:WGS) is one of 233 publicly-traded companies in the “Healthcare Providers & Services” industry, but how does it weigh in compared to its peers? We will compare GeneDx to related businesses based on the strength of its dividends, earnings, valuation, analyst recommendations, profitability, institutional ownership and risk.

Profitability

This table compares GeneDx and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GeneDx	-23.41%	4.12%	2.26%
GeneDx Competitors	-7.78%	-141.29%	-1.53%

Institutional and Insider Ownership

61.7% of GeneDx shares are held by institutional investors. Comparatively, 56.8% of shares of all “Healthcare Providers & Services” companies are held by institutional investors. 25.2% of GeneDx shares are held by insiders. Comparatively, 15.0% of shares of all “Healthcare Providers & Services” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares GeneDx and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
GeneDx	$427.54 million	-$21.02 million	-18.97
GeneDx Competitors	$21.24 billion	$288.54 million	7.18

GeneDx’s peers have higher revenue and earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

GeneDx has a beta of 2, meaning that its stock price is 100% more volatile than the S&P 500. Comparatively, GeneDx’s peers have a beta of 0.97, meaning that their average stock price is 3% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for GeneDx and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeneDx	1	1	7	0	2.67
GeneDx Competitors	1843	7699	13239	815	2.55

GeneDx presently has a consensus target price of $90.86, indicating a potential upside of 31.56%. As a group, “Healthcare Providers & Services” companies have a potential upside of 14.83%. Given GeneDx’s stronger consensus rating and higher possible upside, research analysts plainly believe GeneDx is more favorable than its peers.

Summary

GeneDx beats its peers on 8 of the 13 factors compared.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.